Supriya Lifesci.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE07RO01027
  • NSEID: SUPRIYA
  • BSEID: 543434
INR
907.05
51.85 (6.06%)
BSENSE

Sep 07, 03:14 PM

BSE+NSE Vol: 11.57 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Innova Captab
Bliss GVS Pharma
Aarti Pharma
Senores Pharma.
Morepen Labs.
SPARC
Supriya Lifesci.
P & G Health Ltd
Sanofi India
Sanofi Consumer
Symbiotec Pharma

Why is Supriya Lifescience Ltd ?

1
High Management Efficiency with a high ROE of 17.69%
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 12.24% and Operating profit at 4.80% over the last 5 years
  • PAT(Q) At Rs 24.04 cr has Fallen at -54.1% (vs previous 4Q average)
  • NET SALES(Q) At Rs 189.75 cr has Fallen at -8.3% (vs previous 4Q average)
  • PBDIT(Q) Lowest at Rs 47.46 cr.
4
With ROE of 16.6, it has a Expensive valuation with a 5.7 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 39.19%, its profits have risen by 11.6% ; the PEG ratio of the company is 3
5
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 0.63% over the previous quarter and collectively hold 11.49% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
6
Consistent Returns over the last 3 years
  • Along with generating 39.19% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Supriya Lifesci. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Supriya Lifesci. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Supriya Lifesci.
39.19%
0.83
47.41%
Sensex
-5.77%
-0.43
13.40%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
12.24%
EBIT Growth (5y)
4.80%
EBIT to Interest (avg)
92.14
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.70
Tax Ratio
26.03%
Dividend Payout Ratio
4.28%
Pledged Shares
0
Institutional Holding
11.49%
ROCE (avg)
27.98%
ROE (avg)
17.69%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
34
Industry P/E
37
Price to Book Value
5.68
EV to EBIT
25.98
EV to EBITDA
23.21
EV to Capital Employed
5.98
EV to Sales
7.71
PEG Ratio
2.96
Dividend Yield
0.24%
ROCE (Latest)
23.63%
ROE (Latest)
16.59%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET SALES(Latest six months)

At Rs 466.28 cr has Grown at 41.65%

-11What is not working for the Company
PAT(Q)

At Rs 24.04 cr has Fallen at -54.1% (vs previous 4Q average

NET SALES(Q)

At Rs 189.75 cr has Fallen at -8.3% (vs previous 4Q average

PBDIT(Q)

Lowest at Rs 47.46 cr.

OPERATING PROFIT TO NET SALES (Q)

Lowest at 25.01%

PBT LESS OI(Q)

Lowest at Rs 38.14 cr.

EPS(Q)

Lowest at Rs 2.99

Loading Valuation Snapshot...

Here's what is not working for Supriya Lifesci.

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 38.14 cr has Fallen at -42.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 65.94 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 24.04 cr has Fallen at -54.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 52.37 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Quarterly
At Rs 189.75 cr has Fallen at -8.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 206.97 Cr
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs 47.46 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Lowest at 25.01%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 38.14 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly
Lowest at Rs 2.99
in the last five quarters
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (Rs)